Recent Acquisition Med-Pharmex was acquired by Dechra Pharmaceuticals in 2022 for approximately $260 million, indicating strong industry interest and potential integration opportunities to expand product offerings and distribution channels.

Regulatory Settlement The company settled a U.S. Department of Justice lawsuit with a consent decree after a 2020 complaint, highlighting the importance of compliance solutions and quality assurance products to mitigate legal risks among veterinary pharmaceutical clients.

Market Position With annual revenues between $25 million and $50 million and a workforce of up to 50 employees, Med-Pharmex occupies a niche market segment comparable to mid-sized competitors like Elanco and Intervet, offering opportunities for targeted product sales.

Technology Usage Utilizing a diverse tech stack including SAP, CIM Technologies, and cloud security solutions, Med-Pharmex demonstrates a commitment to digital efficiency, offering potential for sales of advanced supply chain, infrastructure, and cybersecurity solutions.

Growth Opportunities Serving the animal health community with a focus on extending pet health spans and ensuring food safety, Med-Pharmex presents opportunities for innovative health and wellness products, as well as highly accessible, results-driven solutions to support their market expansion.